Clinical Trials Logo

Urticaria Chronic clinical trials

View clinical trials related to Urticaria Chronic.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05461456 Completed - Psoriasis Clinical Trials

Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%

ATOFEX-1
Start date: April 1, 2022
Phase: Phase 1
Study type: Interventional

The investigational lotion is envisaged as an short- and long term "Ease & Prevent" monotherapy for adults and children with mild to moderate eczema. With itch representing the most burdensome symptom in eczema, the main objectives with the lotion is fast and efficient itch relief, high tolerability, and high short- and long term safety. This phase 1 study aims to monitor skin tolerability, and how much of the active compound that is absorbed to the bloodstream.

NCT ID: NCT03632291 Completed - Urticaria Chronic Clinical Trials

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

Start date: April 9, 2019
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of UB-221 as an add-on therapy in patients with Chronic Spontaneous Urticaria.

NCT ID: NCT03111628 Completed - Urticaria Chronic Clinical Trials

Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)

Start date: October 6, 2017
Phase: Phase 4
Study type: Interventional

This is a Phase IV, single-site study that will examine blood cells or tissue obtained from CIU ( chronic idiopathic Urticaria) patients receiving open-label treatment with omalizumab at the current FDA-approved dose of 300 mg/month for 12 weeks in addition to standard therapy with anti-histamines. Results from the 3 Phase III studies in CIU patients provide evidence that a meaningful change in symptoms is apparent at 1-2 wks. The Minimal Important Difference (MID) is achieved by 70% of patients by 2 wks on multiple background drugs for hives. The goal is to identity the IgE bearing cell type associated with clinical symptom change.